Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Mara H. Sherman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7826-3888; OpenAlex author ID A5035829341; NIH RePORTER profile ID 10431069. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 6)
Trials
0
Grants
5
Labs led
2
Collaborators
124
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 grant · 2017: 1 paper · 2018: none · 2019: 1 grant · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers, 1 grant · 2026: 8 papers, 2 grants

Papers 22

  1. Niche-Specific Stromal Crosstalk in Pancreatic Ductal Adenocarcinoma Liver Metastasis. First author DOI 10.1016/j.jcmgh.2026.101907↗
  2. Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-1969↗
  3. Pancreatic Cancer: Translating Tumor Biology into Actionability. First author DOI 10.1158/2159-8290.cd-25-2014↗
  4. IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-25-1612↗
  5. Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer. Co-author DOI 10.1172/jci.insight.192814↗
  6. Invasion status stratifies the composition of the human pancreatic cancer perineural niche Last author DOI 10.64898/2026.08.05.743048↗
  7. Continuous tissue fields organize immune composition in pancreatic cancer Co-author DOI 10.64898/2026.08.22.746444↗
  8. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  9. Author Correction: Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Last author DOI 10.1038/s43018-025-01035-9↗
  10. The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
  11. Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Last author DOI 10.1038/s43018-023-00703-y↗
  12. Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Last author DOI 10.1158/0008-5472.can-24-2860↗
  13. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-36296-4↗
  14. Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-39680-2↗
  15. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Co-author DOI 10.1146/annurev-pathmechdis-031621-024600↗
  16. NUFIP1+ stroma keeps PDAC fed. First author DOI 10.1038/s43018-022-00421-x↗
  17. Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated Fibroblasts. Last author DOI 10.1158/2159-8290.cd-21-0601↗
  18. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Co-author DOI 10.1038/s42255-020-0226-5↗
  19. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. Last author DOI 10.1084/jem.20191805↗
  20. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Co-author DOI 10.1073/pnas.1620164114↗
  21. Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-15-0204↗
  22. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗

Grants 5

  1. Fatty acid signaling in the pancreatic tumor microenvironment R01CA229580↗
  2. Origins and functions of pancreatic cancer-associated fibroblasts R01CA250917↗
  3. Administrative and Biostatistics Core P01CA244114↗
  4. Regulation of cancer cell metabolism and growth by the pancreatic tumor stroma R00CA188259↗
  5. Regulation of cancer cell metabolism and growth by the pancreatic tumor stroma K99CA188259↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohinee Bhattacharyya · 5 shared papers, 2020–2026 · strength 0.93
  2. Laura D Attardi · 1 shared paper, 1 shared grant, 2025–2026 · strength 0.79
  3. Holly Sandborg · 3 shared papers, 2022–2025 · strength 0.78
  4. Rosalie C. Sears · 4 shared papers, 2020–2026 · strength 0.78
  5. Marc Nater · 1 shared paper, 2026 · strength 0.63
  6. Garry Nolan · 1 shared grant, 2025 · strength 0.57
  7. Seung K Kim · 1 shared grant, 2025 · strength 0.57
  8. Steven E Artandi · 1 shared grant, 2025 · strength 0.57
  9. Edgar G. Engleman · 1 shared grant, 2025 · strength 0.57
  10. Walter Gwang-Up Park · 1 shared grant, 2025 · strength 0.57
  11. Marie C. Hasselluhn · 2 shared papers, 2024–2026 · strength 0.50
  12. Marsha Reyngold · 2 shared papers, 2026 · strength 0.49
  13. Kevin C. Soares · 2 shared papers, 2026 · strength 0.49
  14. Wungki Park · 2 shared papers, 2026 · strength 0.49
  15. Eileen Mary O'Reilly · 2 shared papers, 2026 · strength 0.49
  16. Fiyinfolu O. Balogun · 2 shared papers, 2026 · strength 0.49
  17. Christine A. Iacobuzio–Donahue · 2 shared papers, 2026 · strength 0.49
  18. Terry K. Morgan · 2 shared papers, 2024–2025 · strength 0.45
  19. Luis Francisco Diaz · 2 shared papers, 2024–2025 · strength 0.45
  20. Olca Baştürk · 2 shared papers, 2026 · strength 0.45
  21. Nuray Tezcan · 2 shared papers, 2026 · strength 0.45
  22. Kevin Hawthorne · 2 shared papers, 2025–2026 · strength 0.42
  23. Ariana L. Sattler · 2 shared papers, 2022–2026 · strength 0.39
  24. Gregory Lawrence Beatty · 1 shared paper, 2023 · strength 0.39
  25. Zheng Xia · 2 shared papers, 2022–2026 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.